HEALTHIER CHINA THROUGH INNOVATION

Under the China Association of Enterprises with Foreign Investment (CAEFI), the R&D-based Pharmaceutical Association Committee (RDPAC) is a non-profit organization made up of 44 member companies with pharmaceutical R&D capability.


RDPAC Prospect: Three Starting Points of Innovative Drugs for a Healthy China—Release of the Report on Innovation in Pharmaceutical Industry for a Healthy China

March 11, 2021
On the occasion of the Two Sessions, China Association of Enterprises with Foreign Investment R&D-based Pharmaceutical Association Committee (RDPAC) released the Report on Innovation in Pharmaceutical Industry for a Healthy China

Health, Innovation, Cooperation——Two Sessions’ Voice from Heads of 24 Multinational Pharmaceutical Enterprises in China

March 05, 2021
Heads of RDPAC’s 24 multinational pharmaceutical companies in China, on behalf of the pharmaceutical industry, called upon the government, businesses, universities, and research institutes to cooperate, improve relevant policies and strengthen their implementation from diverse areas and to bring practical benefits to patients in China.

A Gift to 2021|"Building China's Pharmaceutical Innovation Ecosystem-Part One of the Series: 2015-2020 Development Review and Future Prospects" is officially released

March 04, 2021
On March 2, 2021, PhIRDA and RDPAC jointly released "Building China's Pharmaceutical Innovation Ecosystem-Part One of the series research reports: 2015-2020 Development Review and Future Prospects"

PUBLICATIONS

DEEPENING THE DRUG INNOVATION ECOSYSTEM REFORM – A PLAN TO DESIGN AND BUILD CHINA’S CLINICAL RESEARCH SYSTEM

Health is the common aspiration of all mankind, and a healthy China constitutes an integral part of the “China Dream”.